Publication Name	World Journal of Clinical Oncology
Manuscript ID	65275
Country	Italy

Received	2021-04-05 13:13
Peer-Review Started	2021-03-03 00:32
To Make the First Decision
Return for Revision	2021-07-06 01:25
Revised	2021-07-07 07:23
Second Decision	2021-09-02 02:54
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2021-09-02 03:36
Articles in Press	2021-09-02 03:36
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2021-10-21 08:54
Publish the Manuscript Online	2021-10-22 09:56

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Hematology
Manuscript Type	Minireviews
Article Title	Role of lenalidomide in the treatment of peripheral T-cell non-Hodgkin lymphomas
Manuscript Source	Invited Manuscript
All Author List	Emanuele Cencini, Alberto Fabbri, Bianca Mecacci and Monica Bocchia
ORCID	Author(s) ORCID Number Emanuele Cencini http://orcid.org/0000-0002-0432-9706 Alberto Fabbri http://orcid.org/0000-0003-2603-9715 Bianca Mecacci http://orcid.org/0000-0002-9762-8843 Monica Bocchia http://orcid.org/0000-0003-3538-3913
Funding Agency and Grant Number
Corresponding Author	Emanuele Cencini, MD, PhD, Doctor, Unit of Hematology, Azienda Ospedaliera Universitaria Senese and University of Siena, Policlinico Le Scotte, viale Bracci 16, Siena 53100, Italy. emanuele.cencini@ao-siena.toscana.it
Key Words	T-cell lymphomas; Lenalidomide; Therapy; Survival; Safety; T follicular helper
Core Tip	T cell lymphoma (TCL) are rare. Lenalidomide is an oral drug with an immunomodulatory, antiangiogenic and direct antineoplastic effect. These peculiar mechanisms of action makes TCL an attractive target for lenalidomide. We have identified 5 clinical trials in which lenalidomide monotherapy was investigated to treat TCL, including cutaneous TCL and adult T-cell lymphoma/Leukemia. Overall response rate was between 10 % and 43%, with prolonged response in a significant proportion of cases and manageable toxicity. Lenalidomide could represent a suitable treatment option for R/R TCL, especially for neoplasms with a T-follicular helper origin, such as angioimmunoblastic TCL.
Publish Date	2021-10-22 09:56
Citation	Cencini E, Fabbri A, Mecacci B, Bocchia M. Role of lenalidomide in the treatment of peripheral T-cell non-Hodgkin lymphomas. World J Clin Oncol 2021; 12(10): 882-896
URL	https://www.wjgnet.com/2218-4333/full/v12/i10/882.htm
DOI	https://dx.doi.org/10.5306/wjco.v12.i10.882

Full Article (PDF)	WJCO-12-882.pdf
Full Article (Word)	WJCO-12-882.docx
Manuscript File	65275_Auto_Edited-JPY.docx
Answering Reviewers	65275-Answering reviewers.pdf
Audio Core Tip	65275-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	65275-Conflict-of-interest statement.pdf
Copyright License Agreement	65275-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	65275-Language certificate.pdf
Peer-review Report	65275-Peer-review(s).pdf
Scientific Misconduct Check	65275-Scientific misconduct check.pdf
Scientific Editor Work List	65275-Scientific editor work list.pdf